<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705679</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-003 (VOICE)</org_study_id>
    <secondary_id>10622</secondary_id>
    <secondary_id>MTN-003</secondary_id>
    <secondary_id>5U01AI068633-05</secondary_id>
    <secondary_id>VOICE</secondary_id>
    <nct_id>NCT00705679</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women</brief_title>
  <official_title>Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Microbicide Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      A new approach to HIV prevention currently being studied includes the use of microbicides,
      substances that kill microbes. Tenofovir disoproxil fumarate (TDF) and
      emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) are oral, FDA-approved, anti-HIV drugs,
      and tenofovir gel is an experimental microbicide. The purpose of this study is to determine
      the safety and effectiveness of daily tenofovir 1% gel compared to a vaginal placebo gel, and
      the safety and effectiveness of oral TDF and oral FTC/TDF compared to an oral placebo in
      preventing HIV infection among women at risk for sexually transmitted infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is necessary to monitor both the adherence and blood levels of microbicides in order to
      gauge its efficacy in a study population. Utilizing an experimental microbicide (tenofovir
      gel) and anti-HIV drugs (TDF, FTC/TDF), this study will measure the effectiveness and safety
      to and blood levels of the three interventions in three regimens given to HIV uninfected
      women.

      The expected duration of participation for each participant ranges from a minimum of 12
      months to a maximum of 38 months. Study participants will be randomly assigned into one of
      five study groups, each with a different regimen. Group 1 participants will take one TDF
      tablet daily and one FTC/TDF placebo tablet daily. Group 2 participants will take one TDF
      placebo tablet daily and one FTC/TDF tablet daily. Group 3 participants will take one TDF
      placebo tablet daily and one FTC/TDF placebo tablet daily. Group 4 participants will apply
      tenofovir 1% gel vaginally once daily. Group 5 participants will apply tenofovir 1% placebo
      gel vaginally once daily.

      Study visits will occur every 28 days after enrollment. Medical history, a physical exam,
      behavioral and adherence assessment, urine and blood collection, and counseling will occur at
      all visits. Blood will also be collected and archived for future research at select visits.
      Pharmacokinetic studies will occur at some visits. A pap smear will occur at select visits.
      Some participants may have hair samples collected on an optional basis at study visits every
      2 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Person-years of Follow-up of Oral TDF and Oral Placebo Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. Note that the data for both of these arms were censored on the date when sites were asked to discontinue treatment in the oral TDF group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Person-years of Follow-up of Oral TDF-FTC and Oral Placebo Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms</measure>
    <time_frame>For up to 30 months of follow-up</time_frame>
    <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse Events</measure>
    <time_frame>Throughout study, up to 2.5 years</time_frame>
    <description>This measure describes the number of participants with elevated serum creatinine levels, the only safety outcome of concern where a significant difference was detected between an active arm and the corresponding placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product</measure>
    <time_frame>Throughout study, up to 2.5 years</time_frame>
    <description>The primary resistance mutations for the study were pre-defined as K65R and K70E (which confer resistance to TDF), and M184I and M184V (which confer resistance to FTC), for their potential to cause a decrease in susceptibility to the study drug. K65R, K70E, and M184I were not detected in HIV-1 from any HIV-1 seroconverters while on study product. The number of HIV-1 seroconverters while on study with the M184V resistance mutation are reported for this outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">5029</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of tenofovir 1% vaginal gel once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of tenofovir placebo gel once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate</intervention_name>
    <description>200 mg/300 mg tablet</description>
    <arm_group_label>2</arm_group_label>
    <other_name>FTC/TDF</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>FTC/TDF placebo</other_name>
    <other_name>Truvada placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300 mg tablet</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>TDF placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir 1% vaginal gel</intervention_name>
    <description>1 gm/100 ml of 1% gel</description>
    <arm_group_label>4</arm_group_label>
    <other_name>TFV</other_name>
    <other_name>9-[2-(Phosphonomethoxy)propyl]adenine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir placebo</intervention_name>
    <description>placebo gel</description>
    <arm_group_label>5</arm_group_label>
    <other_name>TFV placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to provide adequate locator information

          -  Sexually active, defined as having vaginal intercourse at least once in the 3 months
             prior to screening

          -  Agree to not participate in other research studies involving drugs, medical devices,
             or vaginal products for duration of study.

          -  Agree to use effective method of contraception. More information on this criterion can
             be found in the protocol.

        Exclusion Criteria:

          -  HIV infected

          -  Known adverse reaction to any of the study products

          -  Known adverse reaction to latex

          -  Pathologic bone fracture not related to trauma

          -  Non-therapeutic injection drug use in the 12 months prior to screening

          -  Post-exposure prophylaxis for HIV exposure within 6 months prior to enrollment

          -  Last pregnancy outcome 42 days or less prior to enrollment

          -  Gynecologic or genital procedure 42 days or less prior to enrollment

          -  Participation in any other research study involving drugs, medical devices, or vaginal
             products 30 days or less prior to enrollment

          -  Currently using spermicide, interferon or interleukin therapy, or certain medications.
             More information on this criterion can be found in the protocol.

          -  Any significant uncontrolled active or chronic disease. More information on this
             criterion can be found in the protocol.

          -  Certain abnormal laboratory values. More information on this criterion can be found in
             the protocol.

          -  Intends to become pregnant in the 24 months after enrollment

          -  Plans to relocate or travel away from the study site for more than 8 consecutive weeks
             in the 24 months after enrollment

          -  Urinary tract infection

          -  Pelvic inflammatory disease, an STI, or reproductive tract infection requiring
             treatment

          -  Grade 2 or higher pelvic exam finding

          -  Any condition that, in the opinion of the investigator, would interfere with the study

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zvavahera M. Chirenje, MD, FRCOG</last_name>
    <role>Study Chair</role>
    <affiliation>UZ-UCSF Collaborative Research Programme</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanne Marrazzo, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington, Division of Allergy and Infectious Disease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wits Reproductive Health and HIV Institute CRS (WRHI CRS)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto MTN CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overport CRS</name>
      <address>
        <city>Asherville</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatsworth CRS</name>
      <address>
        <city>Chatsworth</city>
        <state>KwaZulu-Natal</state>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eThekwini CRS</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongaat CRS</name>
      <address>
        <city>Tongaat</city>
        <state>KwaZulu-Natal</state>
        <zip>4400</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umkomaas CRS</name>
      <address>
        <city>Umkomaas</city>
        <state>KwaZulu-Natal</state>
        <zip>4170</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verulam CRS</name>
      <address>
        <city>Verulam</city>
        <state>KwaZulu-Natal</state>
        <zip>4340</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Botha's Hill CRS</name>
      <address>
        <city>Westville</city>
        <state>KwaZulu-Natal</state>
        <zip>3630</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isipingo CRS</name>
      <address>
        <city>Westville</city>
        <state>KwaZulu-Natal</state>
        <zip>3630</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAPRISA Aurum CRS</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MU-JHU Research Collaboration CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke South CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zengeza CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spilhaus CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Malawi</country>
  </removed_countries>
  <link>
    <url>http://www.mtnstopshiv.org/</url>
    <description>Click here for the Microbicide Trials Network Web site</description>
  </link>
  <reference>
    <citation>Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006 Feb 28;20(4):543-51.</citation>
    <PMID>16470118</PMID>
  </reference>
  <reference>
    <citation>Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.</citation>
    <PMID>18328009</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>January 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2016</results_first_posted>
  <disposition_first_submitted>May 28, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 24, 2015</disposition_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbicide</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women were recruited from September 2009 through June 2011 from 15 sites in South Africa, Uganda, and Zimbabwe.</recruitment_details>
      <pre_assignment_details>12,320 women were assessed for eligibility and 7,291 were excluded for various reasons, including 2,308 women who were HIV-positive. 5,029 women were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral TDF</title>
          <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate: 300 mg tablet</description>
        </group>
        <group group_id="P2">
          <title>Oral TDF-FTC</title>
          <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
        </group>
        <group group_id="P3">
          <title>Oral Placebo</title>
          <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
        </group>
        <group group_id="P4">
          <title>TFV Gel</title>
          <description>Application of tenofovir 1% vaginal gel once daily
Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
        </group>
        <group group_id="P5">
          <title>Gel Placebo</title>
          <description>Application of tenofovir placebo gel once daily
Tenofovir placebo: placebo gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1007"/>
                <participants group_id="P2" count="1003"/>
                <participants group_id="P3" count="1009"/>
                <participants group_id="P4" count="1007"/>
                <participants group_id="P5" count="1003"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="942"/>
                <participants group_id="P2" count="864"/>
                <participants group_id="P3" count="894"/>
                <participants group_id="P4" count="927"/>
                <participants group_id="P5" count="934"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="115"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all participants enrolled and randomized to a study arm</population>
      <group_list>
        <group group_id="B1">
          <title>Oral TDF</title>
          <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate: 300 mg tablet</description>
        </group>
        <group group_id="B2">
          <title>Oral TDF-FTC</title>
          <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
        </group>
        <group group_id="B3">
          <title>Oral Placebo</title>
          <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
        </group>
        <group group_id="B4">
          <title>TFV Gel</title>
          <description>Application of tenofovir 1% vaginal gel once daily
Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
        </group>
        <group group_id="B5">
          <title>Gel Placebo</title>
          <description>Application of tenofovir placebo gel once daily
Tenofovir placebo: placebo gel</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1007"/>
            <count group_id="B2" value="1003"/>
            <count group_id="B3" value="1009"/>
            <count group_id="B4" value="1007"/>
            <count group_id="B5" value="1003"/>
            <count group_id="B6" value="5029"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="5.1"/>
                    <measurement group_id="B2" value="25.2" spread="5.2"/>
                    <measurement group_id="B3" value="25.3" spread="5.2"/>
                    <measurement group_id="B4" value="25.3" spread="5.2"/>
                    <measurement group_id="B5" value="25.3" spread="5.1"/>
                    <measurement group_id="B6" value="25.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1007"/>
                    <measurement group_id="B2" value="1003"/>
                    <measurement group_id="B3" value="1009"/>
                    <measurement group_id="B4" value="1007"/>
                    <measurement group_id="B5" value="1003"/>
                    <measurement group_id="B6" value="5029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Response to the question: What is your ethnic group or tribe?</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chichewa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lombwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yao</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumbuka</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other African tribe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="84"/>
                    <measurement group_id="B6" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zulu</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="601"/>
                    <measurement group_id="B2" value="587"/>
                    <measurement group_id="B3" value="595"/>
                    <measurement group_id="B4" value="585"/>
                    <measurement group_id="B5" value="571"/>
                    <measurement group_id="B6" value="2939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Xhosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="92"/>
                    <measurement group_id="B6" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bemba</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chewa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tonga</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lozi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shona</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="117"/>
                    <measurement group_id="B6" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ndebele</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Country at time of enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="816"/>
                    <measurement group_id="B2" value="812"/>
                    <measurement group_id="B3" value="815"/>
                    <measurement group_id="B4" value="818"/>
                    <measurement group_id="B5" value="816"/>
                    <measurement group_id="B6" value="4077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="123"/>
                    <measurement group_id="B6" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Some secondary school education or higher</title>
          <description>Response to question: What is your highest level of education?</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Some secondary school education or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="924"/>
                    <measurement group_id="B2" value="929"/>
                    <measurement group_id="B3" value="926"/>
                    <measurement group_id="B4" value="920"/>
                    <measurement group_id="B5" value="923"/>
                    <measurement group_id="B6" value="4622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete primary school education or lower</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Earns own income</title>
          <description>Response to question: Do you earn an income of your own?</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="569"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="586"/>
                    <measurement group_id="B4" value="587"/>
                    <measurement group_id="B5" value="570"/>
                    <measurement group_id="B6" value="2881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="438"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="423"/>
                    <measurement group_id="B4" value="420"/>
                    <measurement group_id="B5" value="432"/>
                    <measurement group_id="B6" value="2147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Live births</title>
          <description>Response to question: How many children have you given birth to who were alive at birth?</description>
          <units>children</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="1.1"/>
                    <measurement group_id="B2" value="1.5" spread="1.1"/>
                    <measurement group_id="B3" value="1.5" spread="1.2"/>
                    <measurement group_id="B4" value="1.5" spread="1.1"/>
                    <measurement group_id="B5" value="1.5" spread="1.2"/>
                    <measurement group_id="B6" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Currently married</title>
          <description>Response to question: Are you currently married?</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="211"/>
                    <measurement group_id="B4" value="210"/>
                    <measurement group_id="B5" value="215"/>
                    <measurement group_id="B6" value="1052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="800"/>
                    <measurement group_id="B2" value="794"/>
                    <measurement group_id="B3" value="798"/>
                    <measurement group_id="B4" value="797"/>
                    <measurement group_id="B5" value="788"/>
                    <measurement group_id="B6" value="3977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>At least 2 male sex partners in the past 3 months</title>
          <description>Includes primary partner and at least 1 other male partner with which the participant has had vaginal sex in the past 3 months</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="244"/>
                    <measurement group_id="B4" value="217"/>
                    <measurement group_id="B5" value="199"/>
                    <measurement group_id="B6" value="1104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="761"/>
                    <measurement group_id="B2" value="782"/>
                    <measurement group_id="B3" value="754"/>
                    <measurement group_id="B4" value="779"/>
                    <measurement group_id="B5" value="793"/>
                    <measurement group_id="B6" value="3869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Episodes of vaginal intercourse in the past 7 days</title>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="2.8"/>
                    <measurement group_id="B2" value="2.5" spread="3.4"/>
                    <measurement group_id="B3" value="2.5" spread="2.6"/>
                    <measurement group_id="B4" value="2.6" spread="3.6"/>
                    <measurement group_id="B5" value="2.6" spread="2.9"/>
                    <measurement group_id="B6" value="2.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Condom use during last vaginal intercourse</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="763"/>
                    <measurement group_id="B2" value="760"/>
                    <measurement group_id="B3" value="742"/>
                    <measurement group_id="B4" value="768"/>
                    <measurement group_id="B5" value="733"/>
                    <measurement group_id="B6" value="3766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="263"/>
                    <measurement group_id="B4" value="239"/>
                    <measurement group_id="B5" value="268"/>
                    <measurement group_id="B6" value="1251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anal sex in the previous 3 months</title>
          <description>A response of 1 or more to the question: In the past 3 months how many times have you had anal sex?</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="176"/>
                    <measurement group_id="B6" value="868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="827"/>
                    <measurement group_id="B2" value="812"/>
                    <measurement group_id="B3" value="823"/>
                    <measurement group_id="B4" value="814"/>
                    <measurement group_id="B5" value="810"/>
                    <measurement group_id="B6" value="4086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injectable contraception use</title>
          <description>Response to question: What method(s) of contraception/family planning is the participant currently using? (Participant could indicate more than one method.)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="709"/>
                    <measurement group_id="B2" value="723"/>
                    <measurement group_id="B3" value="700"/>
                    <measurement group_id="B4" value="707"/>
                    <measurement group_id="B5" value="726"/>
                    <measurement group_id="B6" value="3565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="309"/>
                    <measurement group_id="B4" value="300"/>
                    <measurement group_id="B5" value="277"/>
                    <measurement group_id="B6" value="1464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral pills contraception</title>
          <description>Response to question: What method(s) of contraception/family planning is the participant currently using? (Participant could indicate more than one method.)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="238"/>
                    <measurement group_id="B4" value="238"/>
                    <measurement group_id="B5" value="215"/>
                    <measurement group_id="B6" value="1140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="781"/>
                    <measurement group_id="B2" value="780"/>
                    <measurement group_id="B3" value="771"/>
                    <measurement group_id="B4" value="769"/>
                    <measurement group_id="B5" value="788"/>
                    <measurement group_id="B6" value="3889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection by Chlamydia trachomatis</title>
          <description>Testing was performed with the use of a strand-displacement amplification assay</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="129"/>
                    <measurement group_id="B6" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="884"/>
                    <measurement group_id="B2" value="886"/>
                    <measurement group_id="B3" value="882"/>
                    <measurement group_id="B4" value="891"/>
                    <measurement group_id="B5" value="874"/>
                    <measurement group_id="B6" value="4417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection by Neisseria gonorrhoeae</title>
          <description>Testing was performed with the use of a strand-displacement amplification assay</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="964"/>
                    <measurement group_id="B2" value="976"/>
                    <measurement group_id="B3" value="975"/>
                    <measurement group_id="B4" value="983"/>
                    <measurement group_id="B5" value="967"/>
                    <measurement group_id="B6" value="4865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection by Trichomonas vaginalis</title>
          <description>Testing was performed with the use of the OSOM Trichomonas Rapid Test</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="939"/>
                    <measurement group_id="B2" value="948"/>
                    <measurement group_id="B3" value="943"/>
                    <measurement group_id="B4" value="943"/>
                    <measurement group_id="B5" value="949"/>
                    <measurement group_id="B6" value="4722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Syphilis infection</title>
          <description>Testing was performed with the use of a rapid plasma reagin screening test followed by a confirmatory microhemagglutinin assay</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="988"/>
                    <measurement group_id="B3" value="993"/>
                    <measurement group_id="B4" value="993"/>
                    <measurement group_id="B5" value="992"/>
                    <measurement group_id="B6" value="4960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSV-2 infection</title>
          <description>HSV-2 seropositivity was determined with the use of the HerpeSelect 2 enzyme immunoassay at the time of enrollment; an index value of 3.5 or greater was considered to be a positive result.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                    <measurement group_id="B2" value="449"/>
                    <measurement group_id="B3" value="455"/>
                    <measurement group_id="B4" value="438"/>
                    <measurement group_id="B5" value="465"/>
                    <measurement group_id="B6" value="2289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="520"/>
                    <measurement group_id="B2" value="548"/>
                    <measurement group_id="B3" value="551"/>
                    <measurement group_id="B4" value="566"/>
                    <measurement group_id="B5" value="531"/>
                    <measurement group_id="B6" value="2716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bacterial vaginosis infection</title>
          <description>Bacterial vaginosis was determined by the Nugent score on Gram's staining of vaginal fluid (Nugent score 7-10).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="422"/>
                    <measurement group_id="B2" value="410"/>
                    <measurement group_id="B3" value="401"/>
                    <measurement group_id="B4" value="397"/>
                    <measurement group_id="B5" value="393"/>
                    <measurement group_id="B6" value="2023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="578"/>
                    <measurement group_id="B2" value="592"/>
                    <measurement group_id="B3" value="607"/>
                    <measurement group_id="B4" value="606"/>
                    <measurement group_id="B5" value="604"/>
                    <measurement group_id="B6" value="2987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</title>
        <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up.</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TFV Gel</title>
            <description>Application of tenofovir 1% vaginal gel once daily Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
            <description>Application of placebo gel once daily Tenofovir placebo gel: placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</title>
          <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up.</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="996"/>
                <count group_id="O2" value="996"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1024"/>
                    <measurement group_id="O2" value="1030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</title>
        <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TFV Gel</title>
            <description>Application of tenofovir 1% vaginal gel once daily Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
            <description>Application of placebo gel once daily Tenofovir placebo gel: placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</title>
          <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="996"/>
                <count group_id="O2" value="996"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product</title>
        <description>The primary resistance mutations for the study were pre-defined as K65R and K70E (which confer resistance to TDF), and M184I and M184V (which confer resistance to FTC), for their potential to cause a decrease in susceptibility to the study drug. K65R, K70E, and M184I were not detected in HIV-1 from any HIV-1 seroconverters while on study product. The number of HIV-1 seroconverters while on study with the M184V resistance mutation are reported for this outcome measure.</description>
        <time_frame>Throughout study, up to 2.5 years</time_frame>
        <population>Resistance testing was successfully completed on plasma from 301/312 HIV-1 seroconverters while on study product. 11 participants did not have a resistance result due to no stored plasma, insufficient copies of HIV-1 RNA for extraction, or PCR amplification failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF</title>
            <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate: 300 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral TDF-FTC</title>
            <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O4">
            <title>TFV Gel</title>
            <description>Application of tenofovir 1% vaginal gel once daily
Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
          </group>
          <group group_id="O5">
            <title>Gel Placebo</title>
            <description>Application of tenofovir placebo gel once daily
Tenofovir placebo: placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of HIV-1 Drug Resistance in Women Who Acquire HIV-1 Infection While Using Study Product</title>
          <description>The primary resistance mutations for the study were pre-defined as K65R and K70E (which confer resistance to TDF), and M184I and M184V (which confer resistance to FTC), for their potential to cause a decrease in susceptibility to the study drug. K65R, K70E, and M184I were not detected in HIV-1 from any HIV-1 seroconverters while on study product. The number of HIV-1 seroconverters while on study with the M184V resistance mutation are reported for this outcome measure.</description>
          <population>Resistance testing was successfully completed on plasma from 301/312 HIV-1 seroconverters while on study product. 11 participants did not have a resistance result due to no stored plasma, insufficient copies of HIV-1 RNA for extraction, or PCR amplification failure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M184V mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No M184V mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</title>
        <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TFV Gel</title>
            <description>Application of tenofovir 1% vaginal gel once daily Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
            <description>Application of placebo gel once daily Tenofovir placebo gel: placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms</title>
          <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>cases per 100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="996"/>
                <count group_id="O2" value="996"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.6" upper_limit="7.6"/>
                    <measurement group_id="O2" value="6.8" lower_limit="5.3" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active product will be no more than 25% effective. The trial was designed so that 94 events per pairwise comparison are needed to detect 55% effectiveness while ruling out a lower effectiveness of 25% with 90% power and a false-positive error rate of 0.0025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>The two-sided test a priori threshold for statistical significance is 0.05 against an alternative of 0% effectiveness for estimated effectiveness levels between 33.3% and 50.0%.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional-hazards model was stratified by site.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>A ratio less than 1 indicates a lower rate of HIV infection in the active arm compared to the placebo arm. A ratio more than 1 indicates a higher rate of HIV infection in the active arm compared to the placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Person-years of Follow-up of Oral TDF and Oral Placebo Arms</title>
        <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. Note that the data for both of these arms were censored on the date when sites were asked to discontinue treatment in the oral TDF group.</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF</title>
            <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate: 300 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Person-years of Follow-up of Oral TDF and Oral Placebo Arms</title>
          <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. Note that the data for both of these arms were censored on the date when sites were asked to discontinue treatment in the oral TDF group.</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="993"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823"/>
                    <measurement group_id="O2" value="838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms</title>
        <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF</title>
            <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate: 300 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms</title>
          <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="993"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo Arms</title>
        <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF</title>
            <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate: 300 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo Arms</title>
          <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>cases per 100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="993"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.7" upper_limit="8.3"/>
                    <measurement group_id="O2" value="4.2" lower_limit="2.9" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active product will be no more than 25% effective. The trial was designed so that 94 events per pairwise comparison are needed to detect 55% effectiveness while ruling out a lower effectiveness of 25% with 90% power and a false-positive error rate of 0.0025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>The two-sided test a priori threshold for statistical significance is 0.05 against an alternative of 0% effectiveness for estimated effectiveness levels between 33.3% and 50.0%.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional-hazards model was stratified by site.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
            <estimate_desc>A ratio less than 1 indicates a lower rate of HIV infection in the active arm compared to the placebo arm. A ratio more than 1 indicates a higher rate of HIV infection in the active arm compared to the placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Person-years of Follow-up of Oral TDF-FTC and Oral Placebo Arms</title>
        <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up.</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF-FTC</title>
            <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Person-years of Follow-up of Oral TDF-FTC and Oral Placebo Arms</title>
          <description>Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up.</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="985"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1284"/>
                    <measurement group_id="O2" value="1308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms</title>
        <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF-FTC</title>
            <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms</title>
          <description>Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB).</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="985"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms</title>
        <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
        <time_frame>For up to 30 months of follow-up</time_frame>
        <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF-FTC</title>
            <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms</title>
          <description>This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years).</description>
          <population>All participants randomized except for those with no follow-up HIV testing or those determined to be HIV-positive at the time of randomization by PCR testing of plasma samples stored at the enrollment visit.</population>
          <units>cases per 100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="985"/>
                <count group_id="O2" value="999"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.6" upper_limit="6.1"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.5" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the active product will be no more than 25% effective. The trial was designed so that 94 events per pairwise comparison are needed to detect 55% effectiveness while ruling out a lower effectiveness of 25% with 90% power and a false-positive error rate of 0.0025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <p_value_desc>The two-sided test a priori threshold for statistical significance is 0.05 against an alternative of 0% effectiveness for estimated effectiveness levels between 33.3% and 50.0%.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional-hazards model was stratified by site.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>A ratio less than 1 indicates a lower rate of HIV infection in the active arm compared to the placebo arm. A ratio more than 1 indicates a higher rate of HIV infection in the active arm compared to the placebo arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse Events</title>
        <description>This measure describes the number of participants with elevated serum creatinine levels, the only safety outcome of concern where a significant difference was detected between an active arm and the corresponding placebo arm.</description>
        <time_frame>Throughout study, up to 2.5 years</time_frame>
        <population>All participants randomized (intention-to-treat).</population>
        <group_list>
          <group group_id="O1">
            <title>Oral TDF</title>
            <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate: 300 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Oral TDF-FTC</title>
            <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>Oral Placebo</title>
            <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
          </group>
          <group group_id="O4">
            <title>TFV Gel</title>
            <description>Application of tenofovir 1% vaginal gel once daily
Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
          </group>
          <group group_id="O5">
            <title>Gel Placebo</title>
            <description>Application of tenofovir placebo gel once daily
Tenofovir placebo: placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse Events</title>
          <description>This measure describes the number of participants with elevated serum creatinine levels, the only safety outcome of concern where a significant difference was detected between an active arm and the corresponding placebo arm.</description>
          <population>All participants randomized (intention-to-treat).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1007"/>
                <count group_id="O2" value="1003"/>
                <count group_id="O3" value="1009"/>
                <count group_id="O4" value="1007"/>
                <count group_id="O5" value="1003"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two-sided Fisher's Exact Test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>each participant followed on study up to 2 years, 6 months</time_frame>
      <desc>Participants systematically reported any adverse experiences at monthly follow-up visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral TDF</title>
          <description>TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate: 300 mg tablet</description>
        </group>
        <group group_id="E2">
          <title>Oral TDF-FTC</title>
          <description>TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate: 200 mg/300 mg tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
        </group>
        <group group_id="E3">
          <title>Oral Placebo</title>
          <description>TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
Emtricitabine/tenofovir disoproxil fumarate placebo: placebo tablet
Tenofovir disoproxil fumarate placebo: placebo tablet</description>
        </group>
        <group group_id="E4">
          <title>TFV Gel</title>
          <description>Application of tenofovir 1% vaginal gel once daily
Tenofovir 1% vaginal gel: 1 gm/100 ml of 1% gel</description>
        </group>
        <group group_id="E5">
          <title>Gel Placebo</title>
          <description>Application of tenofovir placebo gel once daily
Tenofovir placebo: placebo gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1-16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomaly in offspring</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratoconus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pericarditis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Internal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gliomatosis cerebri</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Intrapartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Post abortion haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Retained products of conception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (12.1-16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="646" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="740" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="747" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="705" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="715" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="154" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="107" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Genitourinary tract gonococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="84" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="188" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="169" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="170" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="188" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="180" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="183" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="124" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="122" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1007"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="1009"/>
                <counts group_id="E4" subjects_affected="150" subjects_at_risk="1007"/>
                <counts group_id="E5" subjects_affected="126" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In September 2011, the oral TDF arm was discontinued for futility; in November 2011, the TFV gel and gel placebo arms were discontinued for futility. The TDF-FTC and oral placebo arms continued follow-up until the end of study in August 2012.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeanne Marrazzo, MD, MPH, FACP, FIDSA</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-744-3679</phone>
      <email>jmm2@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

